The molecule of programmed cell death 4 (PDCD4) is named based on its upregulation during apoptosis. It is now known that PDCD4 is highly conserved during evolution and widely expressed in the immune cells and non-immune cells of humans and other animals. PDCD4, as an inhibitor of gene transcription and translation, is very important in maintaining the normal function of cells. 1, 2 PDCD4 protein contains an N-terminal domain and two MA-3 domains in the central and C-terminal regions. The MA-3 domains can competitively bind to the translation initiation factor eIF4A with eIF4G to inhibit eIF4A activity and to impact the translation of specific mRNAs containing structured 5′-untranslated regions (5′UTRs). 2 In this eIF4A-dependent manner, PDCD4 is able to inhibit the translational initiation of multiple genes, including tumor suppressor gene p53, apoptosis-related gene pro-caspase 3, autophagy-related gene Atg5 and metabolism-related gene LXR-α. [3] [4] [5] [6] With its N-terminal domain, PDCD4 interacts with specific RNA secondary structures, such as c-myb and A-myb (proto-oncogene) mRNAs, and thereby suppresses translation elongation. 7 The N-terminal domain is also responsible for PDCD4 functional interference by binding to certain proteins, such as poly (A)-binding protein (PABP), Daxx (a scaffold protein with roles in diverse processes, including transcriptional regulation and DNA-damage signaling), transcription factor Twist1 and the p65 subunit of NF-κB. [8] [9] [10] [11] In addition, PDCD4 can also inhibit the activation of the ERK/P38 MAPK pathway and thereby suppress the expression of cytokines, such as Interleukin-10 (IL--10) (Figure 1a ). 12 It has been shown that PDCD4 is often downregulated or virtually eliminated in tumor cells by miR-21, which specifically targets PDCD4 or 5′-CpG methylation in the promotor region, and its forced expression can efficiently inhibit the development and progression of multiple human tumors, including lung, liver, colon, breast, and ovarian cancers and glioma in the brain. 1, 13 However, the precise molecular mechanisms remain unclear. As PDCD4 was first identified as a molecule that promotes tumor cell apoptosis in hepatocellular, ovarian, glioma, breast, and gastric tumors, it is reasonable to speculate that the inhibitory function of PDCD4 in tumorigenesis is attributable to its cell apoptotic function. However, unexpectedly, it plays an anti-apoptotic role in HeLa cells by suppressing pro-casp3 mRNA translation, and it has no impact on apoptosis in colon carcinoma. Therefore, several studies have demonstrated that PDCD4 may exert its inhibitory role on tumor cell growth by depressing the transcription of cyclin-dependent kinase 1 through the upregulation of p21 or by directly binding with transcription factor Twist1, which is sequentially followed by the downregulation of the target gene in prostate cancer cells, such as YB-1. 10 Our current research proposes the novel possibility that the interference of PDCD4 in autophagy in multiple cell types, both in vitro and in vivo, is responsible for its tumor suppressor activity by suppressing the expression of an essential autophagyrelated gene, Atg5, in an eIF4A-dependent manner. 5 Furthermore, we suggest that the inflammation-related tumor is also efficiently attenuated by PDCD4 in a dextran sodium sulfateinduced colitis-associated colon cancer model in mice, as PDCD4 deficiency promotes the development of colitisassociated colorectal carcinoma by accelerating the proliferation of epithelial cells during tumorigenesis via the IL-6/STAT3 pathway. 14 Notably, it has been recently reported that PDCD4 is also involved in autoimmune inflammatory disease and possesses an pro-inflammatory role by selectively inhibiting protein translation in the immune system given that Pdcd4-deficient mice are resistant to autoimmune encephalomyelitis (EAE) and type 1 diabetes, in which lymphocytes preferentially produce anti-inflammatory cytokines. 15 Then, Sheedy et al., 13 indicated in 2010 that lipopolysaccharide (LPS)-induced death can be abolished in Pdcd4-deficient mice by a high level of IL-10 relieving PDCD4 inhibition. Moreover, we demonstrated that Pdcd4-deficient mice are resistant to high fat diet-induced obesity with improved insulin sensitivity and reduced macrophage infiltration and inflammatory cytokine secretion in white adipose tissue (WAT) by inhibiting the expression of liver X receptor (LXR)-α, a master modulator of lipid homeostasis, and its target genes. 6 Recently, we presented evidence that PDCD4 can facilitate high fatinduced atherosclerosis by negatively regulating the expression of antiinflammatory cytokine IL-10 in macrophages in an ERK1/2-and p38-dependent manner, as confirmed by decreased atherosclerotic lesions in Pdcd4( − / − ) and Apoe( − / − ) mice, which can be partly reversed by blockage of IL-10 with a neutralizing antibody. 12 In addition, our research reveals that endogenous PDCD4 can participate in promoting macrophage foam cell formation by suppressing autophagy efflux, whereas with a lack of Pdcd4, oxidized low-density lipoprotein-impaired autophagy efflux can be partly recovered followed by autophagy-mediated lipid breakdown in macrophages, which results in the restraint of macrophage conversion into foam cells. However, PDCD4 also plays a role in inhibitory inflammation in lipopolysaccharide/Dgalactosamine-induced acute liver injury and in a dextran sodium sulfate-induced acute colitis mouse model. 15 Taken together, there is no doubt that PDCD4 acts as a double-edged sword, suppressing tumors (such as lung cancer, liver cancer, and glioma) and acute inflammation (in acute liver injury and acute colitis), as well as promoting autoimmune or chronic inflammation in EAE, diabetes, high fat-induced In summary, the physiologically appropriate level of PDCD4, which is under surveillance and is verified by ubiquitin-proteasome degradation after phosphorylation and the resulting polyubiquitination, is essential to maintaining normal cell function. 1 An imbalance will enable tumor development and progression. In addition, under stress conditions, an abnormal level of PDCD4 in immune or tissue cells is closely involved in diverse diseases as a double-edged sword, which can be good or bad. Even though PDCD4 has become widely accepted as an inhibitor of gene transcription and translation over the past decade, its potential target genes and precise molecular mechanisms in diseases are still worth further investigation and exploration in the future.
